Patents Examined by Raymond Henley, III
  • Inhibitors of secretion of hepatitis B virus antigens
    Patent number: 8921381
    Abstract: Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: December 30, 2014
    Assignees: Baruch S. Blumberg Institute, Philadelphia Health & Education Corporation, Enantigen Therapeutics, Inc.
    Inventors: Xiaodong Xu, Andrea Cuconati, Timothy M. Block, Tong Xiao
  • Eye drops for treatment of conjunctivochalasis
    Patent number: 8912166
    Abstract: An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 16, 2014
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
    Patent number: 8912223
    Abstract: New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: December 16, 2014
    Assignee: Tactical Therapeutics Inc
    Inventor: Rashida A. Karmali
  • Pharmaceutical composition comprising (1r,4r) -6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and a NSAR
    Patent number: 8912226
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a non-steroidal anti-rheumatic drug selected from the group consisting of indometacin, diclofenac, sulindac, tolmetin, zomepirac, aclofenac, bumadizone, etodolac, lonazolac, fentiazac, acemetacin, difenpiramide, oxametacin, proglumetacin, ketorolac, aceclofenac, bufexamac, mefenamic acid, tolfenamic acid, flufenamic acid, meclofenamic acid, and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 16, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Treating cancer with HSP90 inhibitory compounds
    Patent number: 8906885
    Abstract: Methods of treating cancer with a compound of formulae (I) or (1a) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (1a). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (1a); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: December 9, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Iman El-Hariry, David Proia, Vojo Vukovic
  • Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
    Patent number: 8906919
    Abstract: The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian organs, tissues and cells or reducing the extent of damage and death in mammalian organs, tissues and cells. In particular the invention relates to a method for the treatment, amelioration or prevention of non-neuronal and non-myocardial cell or tissue damage or death and for reducing the pain associated with non-neuronal and non-myocardial cell or tissue damage.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: December 9, 2014
    Assignee: Ozteo Pty Ltd
    Inventors: Paul Nathaniel Smith, Steven Michael Weiss
  • Compositions for modulating a kinase cascade and methods of use thereof
    Patent number: 8901297
    Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning calorimetry profile, as well as a unique crystalline structure.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 2, 2014
    Assignee: Kinex Pharmaceuticals, LLC
    Inventors: David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury
  • Carbocyclic nucleosides and their pharmaceutical use and compositions
    Patent number: 8895569
    Abstract: Disclosed are compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating inflammatory skin diseases.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 25, 2014
    Assignee: Cellceutix Corporation
    Inventor: Krishna Menon
  • Amido-amine polymer compositions
    Patent number: 8889738
    Abstract: Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: November 18, 2014
    Assignee: Genzyme Corporation
    Inventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval
  • Methods of treating cancer
    Patent number: 8883737
    Abstract: Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: November 11, 2014
    Assignee: Endocyte, Inc.
    Inventors: Joseph Anand Reddy, Christopher Paul Leamon
  • Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome
    Patent number: 8877800
    Abstract: The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: November 4, 2014
    Assignee: Tioga Pharmaceuticals, Inc.
    Inventor: Allen Mangel
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 8871935
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 28, 2014
    Assignee: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Method for treating skin cancer
    Patent number: 8865772
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: October 21, 2014
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Method for solubilizing metronidazole
    Patent number: 8859603
    Abstract: Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: October 14, 2014
    Assignee: Galderma S.A.
    Inventors: Claire Mallard, Alain Brzokewicz
  • Compositions for the reversible thioesterification of signaling proteins and methods of using same
    Patent number: 8853168
    Abstract: Avicins and other thioesterification agents are used to modify cysteine groups of signaling proteins in order to modify their activity. Pathologies associated with signaling proteins which are regulatable through this method are treated using these thioesterification agents. These pathologies include those involving proteins which modulate physiologic redox status of organisms including arthersclerosis, cancer, bacterial infection, inflammation, and neurological disorders.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: October 7, 2014
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Jordan Gutterman
  • Cyclohexane compounds and their use as antibiotics
    Patent number: 8846645
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 30, 2014
    Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität Konstanz
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
    Patent number: 8828998
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 9, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, David G. Winkler
  • Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
    Patent number: 8822515
    Abstract: This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: September 2, 2014
    Assignee: University of Maryland, Baltimore County
    Inventors: Paul Smith, Dawn Ward
  • Alfentanil composition for the treatment of acute pain
    Patent number: 8815911
    Abstract: There is provided pharmaceutical compositions for the treatment of pain e.g. short-term pain, which compositions comprise a mixture comprising: (a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: August 26, 2014
    Assignee: Orexo AB
    Inventors: Anders Pettersson, Barbro Johansson, Emil Schwan
  • Heterocyclic flaviviridae virus inhibitors
    Patent number: 8815858
    Abstract: The invention is related to anti-viral compounds of formula (A) as defined in the claims, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 26, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Kyla Bjornson, Steven S. Bondy, You-chul Choi, Chien-Hung Chou, Ruchika Mishra, James D. Trenkle, Winston C. Tse, Randall W. Vivian, James G. Taylor